Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy
详细信息 查看全文
- 作者：Muhammad Ali ; Azra Mehmood ; Muhammad Sohail Anjum…
- 关键词：Diabetic cardiomyopathy ; Diazoxide ; Endothelial progenitor cells ; Streptozotocin
- 刊名：Molecular and Cellular Biochemistry
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：410
- 期：1-2
- 页码：267-279
- 全文大小：6,017 KB
- 参考文献：1.Roglic G, Unwin N, Bennett PH et al (2005) The burden of mortality attributable to diabetes realistic estimates for the year 2000. Diabetes Care 28(9):2130-135CrossRef PubMed
2.Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics-012 update: a report from the American Heart Association. Circulation 125:e2–e220PubMedCentral CrossRef PubMed
3.Battiprolu PK, Gillette TG, Wang ZV et al (2010) Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis Mech 7:135-43CrossRef
4.Boudina S, Abel E (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213-223CrossRef PubMed
5.Federici M, Menghini R, Mauriello A et al (2002) Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106(4):466-72CrossRef PubMed
6.He X, Kan H, Cai L et al (2009) Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 46:47-8CrossRef PubMed
7.Giugliano D, Ceriello A, Paolisso G (1995) Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 44:363-68CrossRef PubMed
8.Meigs JB, Larson MG, Fox CS et al (2007) Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 30:2529-535CrossRef PubMed
9.Cai L, Kang YJ (2001) Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1:181-93CrossRef PubMed
10.Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101:2271-276CrossRef PubMed
11.Hohenstein B, Kuo MC, Addabbo F et al (2013) Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney. Am J Physiol Ren Physiol 298:1504-514CrossRef
12.Allegra A, Coppolino G, Bolignano D et al (2009) Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. J Nephrol 22:463-75PubMed
13.Sen S, McDonald SP, Coates PT et al (2011) Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond) 120:263-83CrossRef
14.Alev C, Li M, Asahara T (2011) Endothelial progenitor cells: a novel tool for the therapy of ischemic diseases. Antioxid Redox Signal 15:949-65CrossRef PubMed
15.Grisar JC, Haddad F, Gomari FA et al (2011) Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent. Biomark Med 5:731-44PubMedCentral CrossRef PubMed
16.Kawamoto A, Tkebuchava T, Yamaguchi J et al (2003) Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107:461-68CrossRef PubMed
17.Werner N, Junk S, Laufs U et al (2003) Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 93:17-4CrossRef
18.Ohta T, Kikuta K, Imamura H et al (2006) Administration of ex vivo-expanded bone marrow-derived endothelial progenitor cells attenuates focal cerebral ischemia-reperfusion injury in rats. Neurosurgery 59:679-86CrossRef PubMed
19.Grapensparr L, Olerud J, Vasylovska S et al (2011) The therapeutic role of endothelial progenitor cells in Type 1 diabetes mellitus. Regen Med 6:599-05CrossRef PubMed
20.Georgescu A (2011) Vascular dysfunction in diabetes: the endothelial progenitor cells as new therapeutic strategy. World J Diabetes 2:92-7PubMedCentral CrossRef PubMed
21.Kim KA, Shin YJ, Kim JH et al (2012) Dysfunction of endothelial progenitor cells under diabetic conditions and its underlying mechanisms. Arch Pharmacal Res 35:223-34CrossRef
22.Qu Z, Balkir L, Van Deutekom JC et al (1998) Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 142:1257-267PubMedCentral CrossRef PubMed
23.Niagara MI, Haider H, Jiang S et al (2007) Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 100:545-55CrossRef PubMed
24.Rajapakse N, Kis B, Horiguchi T et al (2003) Diazoxide pretreatment induces delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen peroxide-induced toxicity. J Neurosci Res 73:206-14CrossRef PubMed
25.Loomans CJ, de Koning EJ, Staal FJ et al (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53(1):195-99CrossRef PubMed
26.Khan M, Akhtar S, Mohsin S et al (2011) Growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells. Stem Cells Dev 20:67-5CrossRef PubMed
27 - 作者单位：Muhammad Ali (1)
Azra Mehmood (1)
Muhammad Sohail Anjum (1)
Moazzam Nazir Tarrar (2)
Shaheen N. Khan (1)
Sheikh Riazuddin (1) (2)
1. National Centre of Excellence in Molecular Biology, University of Punjab, 87-West Canal Bank Road, Lahore, Pakistan
2. Allama Iqbal Medical College, University of Health Sciences, Lahore, Pakistan - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Life Sciences
Biochemistry
Medical Biochemistry
Oncology
Cardiology - 出版者：Springer Netherlands
- ISSN：1573-4919
文摘
Type 1 diabetes mellitus (DM) is a strong risk factor for the development of diabetic cardiomyopathy (DCM) which is the leading cause of morbidity and mortality in the type 1 diabetic patients. Stem cells may act as a therapeutic agent for the repair of DCM. However, deteriorated functional abilities and survival of stem cells derived from type 1 diabetic subjects need to be overcome for obtaining potential outcome of the stem cell therapy. Diazoxide (DZ) a highly selective mitochondrial ATP-sensitive K+ channel opener has been previously shown to improve the ability of mesenchymal stem cells for the repair of heart failure. In the present study, we evaluated the effects of DZ preconditioning in improving the ability of streptozotocin-induced type 1 diabetes affected bone marrow-derived endothelial progenitor cells (DM-EPCs) for the repair of DCM in the type 1 diabetic rats. DM-EPCs were characterized by immunocytochemistry, flow cytometry, and reverse transcriptase PCR for endothelial cell-specific markers like vWF, VE cadherin, VEGFR2, PECAM, CD34, and eNOS. In vitro studies included preconditioning of DM-EPCs with 200 μM DZ for 30 min followed by exposure to either 200 μM H2O2 for 2 h (for oxidative stress induction) or 30 mM glucose media (for induction of hyperglycemic stress) for 48 h. Non-preconditioned EPCs with and without exposure to H2O2 and 30 mM high glucose served as controls. These cells were then evaluated for survival (by MTT and XTT cell viability assays), senescence, paracrine potential (by ELISA for VEGF), and alteration in gene expression [VEGF, stromal derived factor-1α (SDF-1α), HGF, bFGF, Bcl2, and Caspase-3]. DZ preconditioned DM-EPCs demonstrated significantly increased survival and VEGF release while reduced cell injury and senescence. Furthermore, DZ preconditioned DM-EPCs exhibited up-regulated expression of prosurvival genes (VEGF, SDF-1α, HGF, bFGF, and Bcl2) on exposure to H2O2, and VEGF and Bcl2 on exposure to hyperglycemia while down regulation of Caspase-3 gene. Eight weeks after type 1 diabetes induction, DZ preconditioned, and non-preconditioned DM-EPCs were transplanted into left ventricle of diabetic rats (at a dose of 2 × 106 DM-EPCs/70 μl serum free medium). After 4 weeks, DZ preconditioned DM-EPCs transplantation improved cardiac function as assessed by Millar’s apparatus. There was decrease in collagen content estimated by Masson’s trichrome and sirius red staining. Furthermore, reduced cell injury was observed as evidenced by decreased expression of Caspase-3 and increased expression of prosurvival genes Bcl2, VEGF, and bFGF by semi-quantitative real-time PCR. In conclusion, the present study demonstrated that DZ preconditioning enhanced EPCs survival under oxidative and hyperglycemic stress and their ability to treat DCM. Keywords Diabetic cardiomyopathy Diazoxide Endothelial progenitor cells Streptozotocin